The HIV drug Kaletra, which was used as a first-line antiviral treatment during the COVID-19 outbreak, will be withdrawn from the domestic market.

The decline in domestic demand is cited as the reason.

On the 23rd, AbbVie Korea reported to the Ministry of Food and Drug Safety that will stop supplying Kaletra Tab(lopinavir + ritonavir) in Korea.

The company explained, "In light of the decrease in demand for Kaletra and the fact that improved substitute options are well in supply, we plan to discontinue its supply."

The company added that the impact on patients is expected to be minimal as improved alternatives are already well-established in the market.